Background: Much scientific, media and patient interest surrounds the risk of venous
thromboembolism (VTE) in women taking combined oral contraceptives (COCs). Objectives …

Background The effects of fourth‐generation drospirenone‐containing combined oral
contraceptives (COC s) on the risk of venous thromboembolism (VTE) are controversial …

Background: An association between oral contraceptive (OC) use and venous
thromboembolism (VTE) has long been recognized. However, no summary estimates of the …

Objective The primary objective of the study was to clarify whether the use of the oral
contraceptive 2 mg dienogest/30 μg ethinylestradiol (DNG/EE) is associated with a higher …

OBJECTIVE: To review primary literature regarding the risk of venous thromboembolism
(VTE) in users of combined oral contraceptives (COCs) containing drospirenone compared …

Objective To examine the risk of non-fatal idiopathic venous thromboembolism in current
users of a combined oral contraceptive containing drospirenone, relative to current users of …

Background Previous studies have provided conflicting results regarding the effect of
drospirenone‐containing oral contraceptive pills (OCP s) on the risk of venous and arterial …

Although the risk of venous thromboembolism is increased among oral contraceptive users
compared with nonusers who are not pregnant and not taking hormones, and some data …

Background Two recent studies, a cohort study from Denmark, and a case-control study from
The Netherlands, have reported increased risks of venous thromboembolism (VTE) among …

The lifetime incidence of venous throm-boembolism for both men and women is estimated at
1 per 1000. 1 Increasing our understanding of the precipitating risk factors, as well as …